Communiqués Intensity Therapeutics, Inc.

Actions

INTS

US45828J1034

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 31/05/2024			Varia. 5j.	Varia. 1 janv.
4,97 ^USD	+0,61 %		-1,58 %	-42,01 %

15/05	Intensity Therapeutics, Inc. nomme Thomas Dubin au conseil d'administration	CI
10/05	Intensity Therapeutics, Inc. conclut un accord de collaboration avec le Groupe suisse de recherche sur le cancer SAKK	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors	15/05	PR
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe	13/05	AQ
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate	10/05	PR
Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	09/05	PR
Intensity Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	19/04	PU
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024	02/04	PR
Portage biotech completes monetization of intensity therapeutics shares	27/03	AQ
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares	26/03	AQ
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024	14/03	PR
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference	21/02	PR
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program	03/01	PR
Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer	12/12	PR
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS	11/12	AQ
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS	08/12	PR
Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium	04/12	AQ
Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium	01/12	PR
Intensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update	13/11	PR
Abstract 1574238: Intratumoral INT230-6 (Cisplatin, Vinblastine, Shao) Alone or with Ipilimumab Prolonged Survival with Favorable Safety and Immune Activation in Adults with Refractory Sarcomas (NCT 03058289)	02/11	PU
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023	02/11	PR
Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma	07/09/23	PR

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Intensity Therapeutics, Inc.

Actions

INTS

US45828J1034

Communiqués

Filtres